PT - JOURNAL ARTICLE AU - Kular, Lara AU - Ewing, Ewoud AU - Needhamsen, Maria AU - Kakhki, Majid Pahlevan AU - Covacu, Ruxandra AU - Gomez-Cabrero, David AU - Brundin, Lou AU - Jagodic, Maja TI - DNA methylation changes in glial cells of the normal-appearing white matter in Multiple Sclerosis patients AID - 10.1101/2021.06.21.21258936 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.21.21258936 4099 - http://medrxiv.org/content/early/2021/06/28/2021.06.21.21258936.short 4100 - http://medrxiv.org/content/early/2021/06/28/2021.06.21.21258936.full AB - Background Multiple Sclerosis (MS), the leading cause of non-traumatic neurological disability in young adults, is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS). Due to the poor accessibility to the target organ, CNS-confined processes underpinning the later progressive form of MS remain elusive thereby limiting treatment options. We aim to examine DNA methylation, a stable epigenetic mark of genome activity, in glial cells to capture relevant molecular changes underlying MS neuropathology.Methods We profiled DNA methylation in nuclei of glial cells, isolated from 38 post-mortem normal-appearing white matter (NAWM) specimens of MS patients (n=8) in comparison to white matter of control individuals (n=14), using Infinium MethylationEPIC BeadChip.Findings We identified 1,226 significant (genome-wide adjusted P-value < 0.05) differentially methylated positions (DMPs) between MS patients and controls. Functional annotation of the altered DMP-genes uncovered alterations of processes related to cellular motility, cytoskeleton dynamics, metabolic processes, synaptic support, neuroinflammation and signaling, such as Wnt and TGF-β pathways. A fraction of the affected genes displayed transcriptional differences in the brain of MS patients, as reported by publically available transcriptomic data. Cell type-restricted annotation of DMP-genes attributed alteration of cytoskeleton rearrangement and extracellular matrix remodelling to all glial cell types, while some processes, including ion transport, Wnt/TGF-β signaling and immune processes were more specifically linked to oligodendrocytes, astrocytes and microglial cells, respectively.Conclusion Our findings strongly suggest that NAWM glial cells are highly altered, even in the absence of lesional insult, collectively exhibiting a multicellular reaction in response to diffuse inflammation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the Swedish Research Council (MJ), the Swedish Association for Persons with Neurological Disabilities (Neuroforbundet MJ, LK, EE, MN), the Swedish Brain Foundation (MJ), the Swedish MS Foundation (LK, MN, EE), the Stockholm County Council - ALF project (MJ), the European Union Horizon 2020 research, innovation programme (grant agreement No 733161, MJ) and the European Research Council (ERC, grant agreement No 818170, MJ), the Knut and Alice Wallenberg Foundation grant, Ake Wilberg Foundation (LK) and Karolinska Institute funds (MJ, LK, MN). LK is supported by a fellowship from the Margaretha af Ugglas Foundation. MPK is supported by McDonald Fellowship from Multiple Sclerosis International Federation (MSIF) and The Bertil and Ebon Norlin Foundation grant. The funders of the study had no role in study design, sample acquisition, data collection, data analysis, data interpretation or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Brain tissues used for this study and obtained from the Multiple Sclerosis and Parkinson s Tissue Bank (Imperial College London) were approved by The Research Ethics Committee for Wales (Wales REC 3) under the reference number: 08/MRE09/31+5 (date of approval: 18 June 2013). All research included in this manuscript conforms with the Declaration of Heksinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe EPIC data that support the findings of this study are available in Gene Expression Omnibus (GEO) database under the accession number GSE166207.